靶向znrf2介导的SLC3A2质膜易位可增强肺腺癌中的铁上吊。

IF 7.3 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Weijie Zhang, Jianjun Li, Jian Zhao, Di Lu, Mengzhu Zhang, Chenkang Ma, Yang Yang, Lei Gu, Jianjie Zhu, Yuanyuan Zeng, Jian-An Huang, Zeyi Liu
{"title":"靶向znrf2介导的SLC3A2质膜易位可增强肺腺癌中的铁上吊。","authors":"Weijie Zhang, Jianjun Li, Jian Zhao, Di Lu, Mengzhu Zhang, Chenkang Ma, Yang Yang, Lei Gu, Jianjie Zhu, Yuanyuan Zeng, Jian-An Huang, Zeyi Liu","doi":"10.1038/s41388-025-03585-9","DOIUrl":null,"url":null,"abstract":"<p><p>Zinc And Ring Finger 2 (ZNRF2), an important protein related to E3 ligases activity, known for its support of cell viability of lung adenocarcinoma (LUAD), remains a functional mystery as its mechanism of action remains largely unknown. SLC3A2, a cell surface transmembrane protein, which regulates intracellular calcium levels and transports L-type amino acids, also has unclear mechanisms, particularly involving its expression and localization. In the present study, we addressed the role of ZNRF2-mediated SLC3A2 plasma membrane translocation, which influences ferroptosis in LUAD. We found that ZNRF2 exhibited ubiquitous expression in LUAD, and supported cell viability via ferroptosis inhibition. Mechanistically, ZNRF2 impacted SLC3A2 membrane localization and ferroptosis by fine-tuning K147-mediated ubiquitination. We subsequently synthesized Peptide K147 to block transportation of the SLC3A2 protein to the plasma membrane, which consequently attenuated the inhibitory effect of ZNRF2 on ferroptosis, thereby preventing tumor cell proliferation both in vitro and in vivo. Finally, we revealed that the ZNRF2- mediated SLC3A2 plasma membrane transport enhanced LUAD chemoresistance, whereas, Peptide K147 facilitated LUAD chemosensitization. Our results demonstrated that ZNRF2-mediated SLC3A2 plasma membrane translocation potentially contributes to the malignant progression and therapeutic resistance in LUAD. This knowledge is beneficial to the future design of advanced cancer therapy.</p>","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":" ","pages":""},"PeriodicalIF":7.3000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting ZNRF2-mediated SLC3A2 plasma membrane translocation enhances ferroptosis in lung adenocarcinoma.\",\"authors\":\"Weijie Zhang, Jianjun Li, Jian Zhao, Di Lu, Mengzhu Zhang, Chenkang Ma, Yang Yang, Lei Gu, Jianjie Zhu, Yuanyuan Zeng, Jian-An Huang, Zeyi Liu\",\"doi\":\"10.1038/s41388-025-03585-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Zinc And Ring Finger 2 (ZNRF2), an important protein related to E3 ligases activity, known for its support of cell viability of lung adenocarcinoma (LUAD), remains a functional mystery as its mechanism of action remains largely unknown. SLC3A2, a cell surface transmembrane protein, which regulates intracellular calcium levels and transports L-type amino acids, also has unclear mechanisms, particularly involving its expression and localization. In the present study, we addressed the role of ZNRF2-mediated SLC3A2 plasma membrane translocation, which influences ferroptosis in LUAD. We found that ZNRF2 exhibited ubiquitous expression in LUAD, and supported cell viability via ferroptosis inhibition. Mechanistically, ZNRF2 impacted SLC3A2 membrane localization and ferroptosis by fine-tuning K147-mediated ubiquitination. We subsequently synthesized Peptide K147 to block transportation of the SLC3A2 protein to the plasma membrane, which consequently attenuated the inhibitory effect of ZNRF2 on ferroptosis, thereby preventing tumor cell proliferation both in vitro and in vivo. Finally, we revealed that the ZNRF2- mediated SLC3A2 plasma membrane transport enhanced LUAD chemoresistance, whereas, Peptide K147 facilitated LUAD chemosensitization. Our results demonstrated that ZNRF2-mediated SLC3A2 plasma membrane translocation potentially contributes to the malignant progression and therapeutic resistance in LUAD. This knowledge is beneficial to the future design of advanced cancer therapy.</p>\",\"PeriodicalId\":19524,\"journal\":{\"name\":\"Oncogene\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.3000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncogene\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41388-025-03585-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogene","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41388-025-03585-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

锌环指2蛋白(Zinc And Ring Finger 2, ZNRF2)是E3连接酶活性相关的重要蛋白,以支持肺腺癌(LUAD)细胞活力而闻名,但其功能机制仍是一个未解之谜。SLC3A2是一种调节细胞内钙水平和转运l型氨基酸的细胞表面跨膜蛋白,其机制也不清楚,特别是其表达和定位。在本研究中,我们研究了znrf2介导的SLC3A2质膜易位在LUAD中影响铁下沉的作用。我们发现ZNRF2在LUAD中普遍表达,并通过抑制铁下垂来支持细胞活力。在机制上,ZNRF2通过微调k147介导的泛素化影响SLC3A2膜定位和铁凋亡。随后,我们合成Peptide K147阻断SLC3A2蛋白向质膜的转运,从而减弱ZNRF2对铁下沉的抑制作用,从而在体外和体内均阻止肿瘤细胞的增殖。最后,我们发现ZNRF2介导的SLC3A2质膜转运增强了LUAD的化疗耐药,而肽K147促进了LUAD的化疗致敏。我们的研究结果表明,znrf2介导的SLC3A2质膜易位可能有助于LUAD的恶性进展和治疗耐药性。这些知识对未来晚期癌症治疗的设计是有益的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Targeting ZNRF2-mediated SLC3A2 plasma membrane translocation enhances ferroptosis in lung adenocarcinoma.

Zinc And Ring Finger 2 (ZNRF2), an important protein related to E3 ligases activity, known for its support of cell viability of lung adenocarcinoma (LUAD), remains a functional mystery as its mechanism of action remains largely unknown. SLC3A2, a cell surface transmembrane protein, which regulates intracellular calcium levels and transports L-type amino acids, also has unclear mechanisms, particularly involving its expression and localization. In the present study, we addressed the role of ZNRF2-mediated SLC3A2 plasma membrane translocation, which influences ferroptosis in LUAD. We found that ZNRF2 exhibited ubiquitous expression in LUAD, and supported cell viability via ferroptosis inhibition. Mechanistically, ZNRF2 impacted SLC3A2 membrane localization and ferroptosis by fine-tuning K147-mediated ubiquitination. We subsequently synthesized Peptide K147 to block transportation of the SLC3A2 protein to the plasma membrane, which consequently attenuated the inhibitory effect of ZNRF2 on ferroptosis, thereby preventing tumor cell proliferation both in vitro and in vivo. Finally, we revealed that the ZNRF2- mediated SLC3A2 plasma membrane transport enhanced LUAD chemoresistance, whereas, Peptide K147 facilitated LUAD chemosensitization. Our results demonstrated that ZNRF2-mediated SLC3A2 plasma membrane translocation potentially contributes to the malignant progression and therapeutic resistance in LUAD. This knowledge is beneficial to the future design of advanced cancer therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncogene
Oncogene 医学-生化与分子生物学
CiteScore
15.30
自引率
1.20%
发文量
404
审稿时长
1 months
期刊介绍: Oncogene is dedicated to advancing our understanding of cancer processes through the publication of exceptional research. The journal seeks to disseminate work that challenges conventional theories and contributes to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers. Emphasis is placed on research shedding light on processes driving metastatic spread and providing crucial insights into cancer biology beyond existing knowledge. Areas covered include the cellular and molecular biology of cancer, resistance to cancer therapies, and the development of improved approaches to enhance survival. Oncogene spans the spectrum of cancer biology, from fundamental and theoretical work to translational, applied, and clinical research, including early and late Phase clinical trials, particularly those with biologic and translational endpoints.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信